RESUMEN
A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent Ga-PSMA PET, which showed a clear response of bone metastases.
Asunto(s)
Neoplasias Óseas/radioterapia , Tomografía de Emisión de Positrones/métodos , Neoplasias de la Próstata/patología , Radio (Elemento)/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias Óseas/secundario , Ácido Edético/análogos & derivados , Isótopos de Galio , Radioisótopos de Galio , Humanos , Masculino , Persona de Mediana Edad , Oligopéptidos , Compuestos Organometálicos , Antígeno Prostático Específico , Radioisótopos/uso terapéutico , Resultado del TratamientoRESUMEN
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.